GLP1R and type 2 diabetes mellitus: In a multinational population-based cohort study that included 51,826 pregnant women diagnosed with T2DM and their infants, the standardized prevalence of major congenital malformations was found to be 8.3% among infants exposed to GLP-1 receptor agonists (GLP1-RA) during the periconceptional period [43].